Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.

ESMO Open · 2022 · PMC9375150 · PMID 35964548

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an encouraging trendno p-value reported

16 An encouraging trend in overall survival (OS) was also observed, with a 12-month OS rate of 94.1% (95% CI 90.3% to 96.4%) with T-DXd versus 85.9% (95% CI 80.9% to 89.7%) with T-DM1 [HR, 0.55 (95% CI 0.36 to 0.86); P = 0.007, which does not cross the prespecified boundary of P < 0.000265 for this analysis]. 16 The benef

also in 355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.